CN109678887B - 一种盐酸头孢卡品酯中间体bcn的制备方法 - Google Patents
一种盐酸头孢卡品酯中间体bcn的制备方法 Download PDFInfo
- Publication number
- CN109678887B CN109678887B CN201811602212.1A CN201811602212A CN109678887B CN 109678887 B CN109678887 B CN 109678887B CN 201811602212 A CN201811602212 A CN 201811602212A CN 109678887 B CN109678887 B CN 109678887B
- Authority
- CN
- China
- Prior art keywords
- reaction
- bcn
- preparation
- salt
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LUXIJPQYUCFVAL-XRLCNELCSA-N 2,2-dimethylpropanoyloxymethyl (6r,7r)-7-[[(z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl]amino]-3-(carbamoyloxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;hydron;chloride;hydrate Chemical compound O.Cl.N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OCOC(=O)C(C)(C)C)=O)C(=O)\C(=C/CC)C1=CSC(N)=N1 LUXIJPQYUCFVAL-XRLCNELCSA-N 0.000 title claims abstract description 36
- 229950004627 cefcapene pivoxil Drugs 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 238000006243 chemical reaction Methods 0.000 claims abstract description 76
- 150000008064 anhydrides Chemical class 0.000 claims abstract description 42
- 238000002425 crystallisation Methods 0.000 claims abstract description 31
- 230000008025 crystallization Effects 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 238000006482 condensation reaction Methods 0.000 claims abstract description 17
- 230000021235 carbamoylation Effects 0.000 claims abstract description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 60
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 57
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 238000006460 hydrolysis reaction Methods 0.000 claims description 20
- 229940043279 diisopropylamine Drugs 0.000 claims description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 15
- 150000001412 amines Chemical class 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 239000007859 condensation product Substances 0.000 claims description 12
- 239000002243 precursor Substances 0.000 claims description 12
- XIXNSLABECPEMI-VURMDHGXSA-N (z)-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-thiazol-4-yl]pent-2-enoic acid Chemical compound CC\C=C(/C(O)=O)C1=CSC(NC(=O)OC(C)(C)C)=N1 XIXNSLABECPEMI-VURMDHGXSA-N 0.000 claims description 11
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 claims description 11
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 11
- 238000004821 distillation Methods 0.000 claims description 10
- 125000004494 ethyl ester group Chemical group 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 9
- 239000012044 organic layer Substances 0.000 claims description 9
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 238000007670 refining Methods 0.000 claims description 8
- 238000006170 formylation reaction Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 claims description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 claims description 3
- QARBMVPHQWIHKH-KHWXYDKHSA-N methanesulfonyl chloride Chemical group C[35S](Cl)(=O)=O QARBMVPHQWIHKH-KHWXYDKHSA-N 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 238000003756 stirring Methods 0.000 description 14
- 238000001816 cooling Methods 0.000 description 11
- 238000004811 liquid chromatography Methods 0.000 description 10
- 238000007599 discharging Methods 0.000 description 9
- 238000010606 normalization Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000005070 sampling Methods 0.000 description 8
- DIOSHTLNZVXJOF-UHFFFAOYSA-N 2,5-bis(3-oxobutanoylamino)benzenesulfonic acid Chemical compound CC(=O)CC(=O)NC1=CC=C(NC(=O)CC(C)=O)C(S(O)(=O)=O)=C1 DIOSHTLNZVXJOF-UHFFFAOYSA-N 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000007306 turnover Effects 0.000 description 6
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 239000011229 interlayer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- BYHXLDZDSZVDJH-UHFFFAOYSA-N acetic acid;1,3-thiazole Chemical compound CC(O)=O.C1=CSC=N1 BYHXLDZDSZVDJH-UHFFFAOYSA-N 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229930186147 Cephalosporin Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- OHLRLMWUFVDREV-UHFFFAOYSA-N ethyl 4-chloro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CCl OHLRLMWUFVDREV-UHFFFAOYSA-N 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940124588 oral cephalosporin Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/04—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
- C07D501/34—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Description
峰号 | 保留时间 | 面积 | 高度 | 面积% | 理论塔板数(USP) | 拖尾因子 |
1 | 2.684 | 1390 | 142 | 0.011 | 375 | -- |
2 | 2.852 | 2578 | 269 | 0.019 | 1914 | -- |
3 | 3.419 | 12389 | 1299 | 0.094 | 3127 | 0.830 |
4 | 7.721 | 2340 | 137 | 0.018 | 4549 | -- |
5 | 9.001 | 49456 | 2437 | 0.374 | 4386 | 0.967 |
6 | 10.900 | 7105 | 362 | 0.054 | -- | -- |
7 | 11.204 | 11160 | 464 | 0.084 | 1572 | -- |
8 | 12.709 | 13071086 | 505607 | 98.841 | 5487 | 1.049 |
9 | 14.393 | 35801 | 1106 | 0.271 | 4721 | -- |
10 | 15.564 | 4108 | 151 | 0.031 | 6987 | 1.139 |
11 | 19.568 | 7290 | 220 | 0.055 | 7046 | 0.934 |
12 | 25.882 | 19630 | 385 | 0.148 | 6158 | 1.333 |
总计 | 13224333 | 512579 | 100.000 |
峰号 | 保留时间 | 面积 | 高度 | 面积% | 理论塔板数(USP) | 拖尾因子 |
1 | 2.854 | 1397 | 164 | 0.017 | 2454 | -- |
2 | 3.388 | 1184 | 129 | 0.014 | 2630 | -- |
3 | 6.994 | 9936 | 528 | 0.121 | 3037 | 1.077 |
4 | 7.813 | 2494 | 161 | 0.030 | 5520 | 0.914 |
5 | 9.109 | 69313 | 3574 | 0.841 | 4894 | 0.997 |
6 | 11.574 | 47214 | 1436 | 0.573 | 2926 | 0.741 |
7 | 12.895 | 8024620 | 301267 | 97.351 | 5341 | 1.020 |
8 | 14.559 | 15208 | 339 | 0.184 | 1464 | -- |
9 | 15.852 | 14040 | 473 | 0.170 | 6358 | 1.007 |
10 | 17.350 | 8098 | 238 | 0.098 | 5643 | 1.014 |
11 | 19.893 | 31121 | 888 | 0.378 | 7130 | 0.899 |
12 | 26.416 | 18335 | 328 | 0.222 | 6653 | 1.567 |
总计 | 8242962 | 309524 | 100.000 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811602212.1A CN109678887B (zh) | 2018-12-26 | 2018-12-26 | 一种盐酸头孢卡品酯中间体bcn的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811602212.1A CN109678887B (zh) | 2018-12-26 | 2018-12-26 | 一种盐酸头孢卡品酯中间体bcn的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109678887A CN109678887A (zh) | 2019-04-26 |
CN109678887B true CN109678887B (zh) | 2020-08-14 |
Family
ID=66189740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811602212.1A Active CN109678887B (zh) | 2018-12-26 | 2018-12-26 | 一种盐酸头孢卡品酯中间体bcn的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109678887B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110204556B (zh) * | 2019-07-16 | 2020-09-18 | 重庆医药高等专科学校 | (rs)-甲氧基头孢西丁的制备方法 |
CN111039959B (zh) * | 2019-12-20 | 2021-05-04 | 湖北凌晟药业有限公司 | 一种头孢卡品酯前体酸bcn的纯化方法 |
CN111440197A (zh) * | 2020-04-09 | 2020-07-24 | 辽宁美亚制药有限公司 | 一种头孢曲松钠的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT400717B (de) * | 1993-07-30 | 1996-03-25 | Biochemie Gmbh | Neue guanidin- und amidinsalze von 7-amino-3- hydroxymethyl-3-cephem-4-carbonsäure |
CN1091085C (zh) * | 1999-12-03 | 2002-09-18 | 山东淄博新华-肯孚制药有限公司 | 一种回收含氮有机碱的方法 |
CN105131017B (zh) * | 2015-09-09 | 2017-07-25 | 山东罗欣药业集团股份有限公司 | 一种盐酸头孢卡品酯的制备方法 |
CN105254649B (zh) * | 2015-11-02 | 2018-06-26 | 湖北凌晟药业有限公司 | 一种盐酸头孢卡品酯的制备方法 |
-
2018
- 2018-12-26 CN CN201811602212.1A patent/CN109678887B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN109678887A (zh) | 2019-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109678887B (zh) | 一种盐酸头孢卡品酯中间体bcn的制备方法 | |
IE882108L (en) | Azithromycin dihydrate | |
EP2712865B1 (en) | Improved process for the preparation of ambrisentan | |
HRP20010514A2 (en) | Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament | |
WO2019030711A1 (en) | POLYMORPHS AND CO-CRYSTALS OF ROXADUSTAT | |
CN109438336B (zh) | 一种瑞戈非尼水合物的制备方法 | |
WO2011007895A1 (ja) | 貧溶媒添加法による2-(3-シアノ-4-イソブチルオキシフェニル)-4-メチル-5-チアゾールカルボン酸の結晶多形体の製造方法 | |
EP0304941B1 (en) | Pharmaceutically useful polymorphic modification of buspirone | |
CN106565716B (zh) | 一种Idelalisib晶型A及其制备方法 | |
CN104788429B (zh) | 一种通过脱除三苯甲基保护基制备沙坦类药物的方法 | |
CN103601737B (zh) | 一种盐酸头孢替安的制备方法 | |
CN104817557B (zh) | 一种盐酸莫西沙星的稳定晶型及其制备方法 | |
CN107722056A (zh) | 磷酸特地唑胺的制备方法 | |
CN109134501A (zh) | 一种1/5水头孢拉定化合物及其药物组合物制剂 | |
CN109153652B (zh) | 1-(芳基甲基)喹唑啉-2,4(1h,3h)-二酮的制备工艺 | |
WO2013120496A1 (en) | Process for the preparation of linezolid in crystalline form and salts thereof | |
JP2020200300A (ja) | エルデカルシトールの新規な結晶形およびその調製方法、および使用に関する | |
CN114540454B (zh) | 一种酶法合成盐酸头孢卡品匹酯的方法及其合成中间体 | |
CN114349770B (zh) | 一种凝血FXa抑制剂的制备方法 | |
EP2690097B1 (en) | Method for crystallizing glutamic acid benzyl ester n-carboxylic anhydride | |
CN110117263B (zh) | 2-氨基-5-酰基噻唑衍生物及其合成方法 | |
CN108570061B (zh) | 扎布沙星的制备方法 | |
CN109485639B (zh) | 一种舒尼替尼制备方法 | |
CN111171050B (zh) | 一种盐酸头孢卡品酯的制备方法 | |
TW202330535A (zh) | 一種dpp-iv抑制劑及其關鍵中間體的製備方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 441000 Xiangcheng Economic Development Zone, Xiangcheng District, Xiangyang City, Hubei Province Patentee after: Hubei Lingsheng Pharmaceutical Co.,Ltd. Address before: 441000 Xiangyang City, Hubei Province Xiangcheng Economic Development Zone No. 10 Road 1 Patentee before: HUBEI LINGSHENG PHARMACEUTICAL CO.,LTD. |
|
CP03 | Change of name, title or address | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for preparing intermediate BCN of ceftriaxone hydrochloride ester Granted publication date: 20200814 Pledgee: Agricultural Bank of China Limited Xiangyang High tech Zone Branch Pledgor: Hubei Lingsheng Pharmaceutical Co.,Ltd. Registration number: Y2024980002009 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |